Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr1748 Inhibitors

Olr1748 inhibitors represent a class of chemical compounds that target the olfactory receptor OR1748, a G-protein-coupled receptor (GPCR) primarily involved in the detection of specific odorants. The Olr1748 receptor is part of a broader family of olfactory receptors that mediate the sense of smell through intricate signaling pathways. These inhibitors are designed to bind selectively to the OR1748 receptor, effectively blocking its interaction with natural ligands and disrupting the normal signal transduction processes. Structurally, Olr1748 inhibitors often contain specific moieties that enable high-affinity binding to the receptor's active site, preventing conformational changes necessary for receptor activation. This blockade at the molecular level can result in a significant reduction or complete inhibition of signal transmission through the olfactory pathway, providing a valuable tool for studying the mechanistic aspects of olfaction and receptor function.

Chemically, Olr1748 inhibitors may vary in their backbone structures, but they generally share common features such as lipophilic domains that interact with the hydrophobic regions of the receptor, as well as polar functional groups that engage in hydrogen bonding with key residues within the receptor's binding pocket. The design and synthesis of these inhibitors often involve sophisticated techniques like structure-based drug design (SBDD) and computational modeling to predict binding affinity and specificity. Additionally, the optimization of Olr1748 inhibitors requires a detailed understanding of the receptor's 3D structure, ligand-binding kinetics, and the physicochemical properties that govern receptor-ligand interactions. These inhibitors are invaluable for probing the functional dynamics of OR1748, offering insights into the structural biology of olfactory receptors and their role in sensory perception.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Erlotinib Hydrochloride

183319-69-9sc-202154
sc-202154A
10 mg
25 mg
$75.00
$121.00
33
(1)

EGFR tyrosine kinase inhibitor, potentially disrupting signaling pathways that could regulate Olr1748.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$114.00
$166.00
$947.00
19
(1)

MEK inhibitor, might modulate MAPK/ERK signaling, influencing Olr1748 activity.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Inhibits multiple kinases, could affect pathways influencing Olr1748, like angiogenesis or cell proliferation.

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

CDK4/6 inhibitor, might impact cell cycle regulation pathways affecting Olr1748.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

Proteasome inhibitor, could affect protein degradation mechanisms relevant to Olr1748.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

BCR-ABL tyrosine kinase inhibitor, potentially disrupting signaling pathways regulating Olr1748.

Nilotinib

641571-10-0sc-202245
sc-202245A
10 mg
25 mg
$209.00
$413.00
9
(1)

BCR-ABL kinase inhibitor, might affect cell proliferation and survival pathways influencing Olr1748.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Src family kinase inhibitor, could alter cell proliferation and survival pathways affecting Olr1748.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Dual EGFR and HER2 inhibitor, potentially modulating signaling pathways relevant to Olr1748's function.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$153.00
$938.00
5
(0)

Multi-targeted receptor tyrosine kinase inhibitor, might disrupt several signaling pathways involving Olr1748.